Yoshinobu Ikeno
Kyoto University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yoshinobu Ikeno.
Annals of Surgery | 2017
Yukihiro Okuda; Kojiro Taura; Kenji Yoshino; Yoshinobu Ikeno; Takahiro Nishio; Gen Yamamoto; Kazutaka Tanabe; Yukinori Koyama; Etsuro Hatano; Shiro Tanaka; Shinji Uemoto
Objective: The aim of this study was to evaluate the usefulness of the Mac-2 binding protein glycosylation isomer (M2BPGi) for the prediction of posthepatectomy liver failure (PHLF) in hepatocellular carcinoma (HCC) patients. Summary Background Data: M2BPGi is a novel serum marker of liver fibrosis. The usefulness of M2BPGi for the prediction of PHLF has not been evaluated. Methods: Clinicopathological data were analyzed in 138 HCC patients who underwent liver resection between August 2011 and November 2014. PHLF was evaluated according to the definition of the International Study Group of Liver Surgery. Performance of preoperative parameters in predicting PHLF was determined using receiver operating characteristic (ROC) analysis. Results: Serum M2BPGi level correlated with the METAVIR fibrosis score. M2BPGi levels of hepatitis C virus (HCV)-positive patients were significantly higher than those of HCV-negative patients, even in the same fibrosis stage. PHLF ≥ Grade B developed in 19 patients (13.8%). The area under the ROC curve (AUROC) of M2BPGi for the prediction of PHLF ≥ Grade B was 0.71. In multivariate analysis, M2BPGi [odds ratio (OR): 2.08, 95% confidence interval (CI) 1.28–3.55], platelet count (OR: 0.39, 95% CI 0.18–0.80), and resection rate (OR: 2.71, 95% CI 1.46–5.40) were the significant factors associated with PHLF ≥ Grade B. The AUROC of the PHLF index defined by these factors was 0.81. Notably, in patients with HCV infection, the predictive ability of M2BPGi for PHLF (AUROC 0.85) was the best among the preoperative parameters. Conclusions: M2BPGi is a useful predictor of PHLF, especially in patients with HCV infection.
Pancreas | 2017
Gen Yamamoto; Kojiro Taura; Keiko Iwaisako; Masataka Asagiri; Shinji Ito; Yukinori Koyama; Kazutaka Tanabe; Kohta Iguchi; Motohiko Satoh; Takahiro Nishio; Yukihiro Okuda; Yoshinobu Ikeno; Kenji Yoshino; Satoru Seo; Etsuro Hatano; Shinji Uemoto
Objectives The origin of collagen-producing myofibroblasts in pancreatic fibrosis is still controversial. Pancreatic stellate cells (PSCs), which have been recognized as the pancreatic counterparts of hepatic stellate cells (HSCs), are thought to play an important role in the development of pancreatic fibrosis. However, sources of myofibroblasts other than PSCs may exist because extensive studies of liver fibrosis have uncovered myofibroblasts that did not originate from HSCs. This study aimed to characterize myofibroblasts in an experimental pancreatic fibrosis model in mice. Methods We used transgenic mice expressing green fluorescent protein via the collagen type I &agr;1 promoter and induced pancreatic fibrosis with repetitive injections of cerulein. Results Collagen-producing cells that are negative for glial fibrillary acidic protein (ie, not derived from PSCs) exist in the pancreas. Pancreatic stellate cells had different characteristics from those of HSCs in a very small possession of vitamin A using mass spectrometry and a low expression of lecithin retinol acyltransferase. The microstructure of PSCs was entirely different from that of HSCs using flow cytometry and electron microscopy. Conclusions Our study showed that characteristics of PSCs are different from those of HSCs, and myofibroblasts in the pancreas might be derived not only from PSCs but also from other fibrogenic cells.
Liver Transplantation | 2018
Kenji Yoshino; Kojiro Taura; Yoshinobu Ikeno; Yukihiro Okuda; Takahiro Nishio; Gen Yamamoto; Satoru Seo; Shintaro Yagi; Koichiro Hata; Toshimi Kaido; Hideaki Okajima; Shinji Uemoto
Living donor right hepatectomy (LDRH) is a common procedure in adult‐to‐adult living donor liver transplantation, but it is associated with a higher risk of posthepatectomy liver failure (PHLF) compared with left hepatectomy because of a smaller remnant. We identified risk factors for PHLF and other complications in LDRH, verified the appropriateness of the criteria, and explored the possibility of adjusting the minimum remnant liver volume (RLV) based on individual risk. Between October 2005 and November 2017, 254 donors undergoing LDRH at Kyoto University Hospital were enrolled. Clinical data were collected retrospectively. All complications were graded according to the Clavien‐Dindo classification. No donors had grade 4 or 5 complications or clinically significant grade B or C PHLF. Grade A PHLF occurred in 30 donors (11.8%). Male sex (P = 0.01), lower preoperative platelet count (PLT; P = 0.01), higher prothrombin time–international normalized ratio (P = 0.03), higher total bilirubin (P = 0.01), smaller RLV (P = 0.03), and greater blood loss (P = 0.04) were associated with increased risk of PHLF in the univariate analysis, whereas PLT, RLV, and blood loss remained significant in the multivariate analysis. Grade 2 or 3 complications were observed in 32 (12.6%) donors. Higher body mass index (BMI; P = 0.002) and larger blood loss (P = 0.02) were identified as risk factors for complications (Clavien‐Dindo grade ≥ 2) in univariate analysis. Only BMI remained significant in the multivariate analysis. In conclusion, LDRH is performed safely with acceptable morbidity under the current criteria. Minimum RLV may be marginally adjusted by PLT and reducing intraoperative blood loss minimizes PHLF risk. Liver Transplantation 00 000–000 2018 AASLD.
Journal of Translational Medicine | 2018
Yoshinobu Ikeno; Satoru Seo; Keiko Iwaisako; Tomoaki Yoh; Yuji Nakamoto; Hiroaki Fuji; Kojiro Taura; Hideaki Okajima; Toshimi Kaido; Shimon Sakaguchi; Shinji Uemoto
BackgroundSurgical resection remains the mainstay of curative treatment for intrahepatic cholangiocarcinoma (ICC). Prognosis after surgery is unsatisfactory despite improvements in treatment and post-operative clinical management. Despite developments in the molecular profiling of ICC, the preoperative prediction of prognosis remains a challenge. This study aimed to identify clinical prognostic indicators by investigating the molecular profiles of ICC and evaluating the preoperative imaging data of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET).MethodsA retrospective analysis was performed on 50 consecutive patients with ICC who underwent curative hepatectomy after 18F-FDG-PET examination. To evaluate the molecular profiles of ICC, KRAS mutation status was assessed in resected specimens. For the assessment of glucose uptake, we observed the expression of glucose transporter-1 (GLUT-1) by immunohistochemistry. The data of 18F-FDG-PET were re-evaluated as follows: maximum standardized uptake value, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Cut-off values were determined using receiver operating characteristic (ROC) curve analysis. Cumulative overall survival (OS) was analyzed using the Kaplan–Meier analysis.ResultsOverall, 16 (32.0%) patients had mutations in KRAS. Patients with mutated KRAS exhibited shorter OS than those with wild-type KRAS (5-year OS, 0% vs. 35.1%, P < 0.001). GLUT-1 expression was significantly higher in tumors with mutated KRAS than in tumors with wild-type KRAS (median, 4.0 vs. 1.0, P < 0.001). Survival was significantly different when stratified by expression of GLUT-1 (5-year OS, 0% vs. 46.5%, P <0.001). Among the 18F-FDG-PET parameters, the MTV and TLG were significantly higher in the mutated KRAS group than in the wild-type KRAS group (P = 0.013 and P = 0.026, respectively). ROC curve analysis revealed a cut-off value of 38 for the MTV, with the highest accuracy (area under the curve = 0.789; 95% confidence interval, 0.581–0.902) for predicting KRAS mutation. This cut-off value permitted stratification of OS (high vs. low: 5-year OS, 13.1% vs. 36.7%, P = 0.008).ConclusionsHigh MTV is associated with KRAS mutation and poor postoperative outcomes in patients with ICC, suggesting that the MTV of ICC measured by 18F-FDG-PET may provide useful information for tumor molecular profiles and prognosis.
Asian Journal of Endoscopic Surgery | 2018
Hiroaki Fuji; Satoru Seo; Rei Toda; Tomoaki Yoh; Yoshinobu Ikeno; Ken Fukumitsu; Takamichi Ishii; Kojiro Taura; Etsuro Hatano; Toshimi Kaido; Shinji Uemoto
Surgery for Child–Pugh B liver function is considered risky because of its high morbidity rate and the acceptable indication criteria for laparoscopic liver resection (LLR) for Child–Pugh B patients have not been identified. We conducted a retrospective cohort study to determine the optimal introduction of LLR for Child–Pugh B patients based on our single‐institute experience.
Anticancer Research | 2018
Yoshinobu Ikeno; Satoru Seo; Gen Yamamoto; Yuji Nakamoto; Yusuke Uemoto; Hiroaki Fuji; Kenji Yoshino; Tomoaki Yoh; Kojiro Taura; Shinji Uemoto
Background/Aim: Preoperative identification of the invasive component remains challenging in intraductal papillary neoplasm of the bile duct (IPNB). We evaluated the ability of preoperative 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) to differentiate between non-invasive IPNB, invasive IPNB, and papillary cholangiocarcinoma (CCA). Patients and Methods: The maximum standardized uptake values (SUVmax) of 11 patients with IPNB (6 non-invasive and 5 invasive) and 20 with papillary CCA who underwent pre-surgical 18F-FDG-PET were assessed. The SUVmax cut-off that predicts an invasive component was determined using receiver operating characteristic (ROC) curve analysis. Results: The SUVmax in patients with invasive IPNB and papillary CCA were significantly higher than in patients with non-invasive IPNB (p=0.035 and 0.0025, respectively). ROC curve analysis revealed an optimal SUVmax cut-off of 4.5, which had 94.5% accuracy, 76.0% sensitivity, and 100% specificity. Conclusion: Our data suggest that the preoperative 18F-FDG-PET SUVmax can differentiate non-invasive IPNB from invasive IPNB and papillary CCA.
Surgery | 2016
Takahiro Nishio; Kojiro Taura; Yukinori Koyama; Kazutaka Tanabe; Gen Yamamoto; Yukihiro Okuda; Yoshinobu Ikeno; Satoru Seo; Kentaro Yasuchika; Etsuro Hatano; Hideaki Okajima; Toshimi Kaido; Shiro Tanaka; Shinji Uemoto
Annals of Surgical Oncology | 2017
Tomoaki Yoh; Satoru Seo; Etsuro Hatano; Kojiro Taura; Hiroaki Fuji; Yoshinobu Ikeno; Yukihiro Okuda; Kentaro Yasuchika; Toshimi Kaido; Hideaki Okajima; Shinji Uemoto
World Journal of Surgery | 2018
Tomoaki Yoh; Etsuro Hatano; Satoru Seo; Yukihiro Okuda; Hiroaki Fuji; Yoshinobu Ikeno; Kojiro Taura; Kentaro Yasuchika; Hideaki Okajima; Toshimi Kaido; Shinji Uemoto
Journal of Gastroenterology | 2017
Takahiro Nishio; Kojiro Taura; Keiko Iwaisako; Yukinori Koyama; Kazutaka Tanabe; Gen Yamamoto; Yukihiro Okuda; Yoshinobu Ikeno; Kenji Yoshino; Yosuke Kasai; Masayuki Okuno; Satoru Seo; Takaki Sakurai; Masataka Asagiri; Etsuro Hatano; Shinji Uemoto